Abstract t
WeWe immunohistochemicaliy labeled 72 biopsy specimensspecimens from the extrahepatic biliary tree and pancreaspancreas for Dpc4 protein and correlated expression withwith histologic diagnosis and patient follow-up. SpecimensSpecimens were classified histologically as follows: nonneoplastic,nonneoplastic, 35; neoplastic, 22; atypical, 15 . Loss of expressionexpression of Dpc4 protein was identified in 12 specimens;specimens; 11 were histologically diagnostic of carcinoma.carcinoma. The 12th specimen was from a patient whosewhose biopsy specimen initially was diagnosed as "atypical,""atypical," but clinical follow-up revealed adenocarcinoma.adenocarcinoma. Of the 12 atypical biopsy specimens withwith intact expression for Dpc4, follow-up later revealedrevealed that 10 were adenocarcinoma. Loss of expressionexpression ofDpc4 protein was never identified in a benignbenign specimen.
ImmunohistochemicalImmunohistochemical labeling for the Dpc4 gene productproduct is a specific marker of carcinoma in biopsy specimensspecimens of the pancreas and extrahepatic bile ducts andand is marginally helpful in classifying atypical specimens.specimens. The sensitivity for carcinoma is low. This latterlatter finding is not unexpected, because the DPC4 tumortumor suppressor gene is inactivated in only about half ofof pancreatic and biliary malignant neoplasms. Importantly,Importantly, loss ofDpc4 expression has been reported inin in situ carcinomas, suggesting that loss of expression shouldshould not be equated with invasive carcinoma.
Thee DPC4 gene is inactivated in approximately 55% of pancreaticc ductal adenocarcinomas and in 15% to 55% of extrahepaticc biliary adenocarcinomas. 1 " 5 Inactivation occurs byy 1 of 2 mechanisms: (1) intragenic mutation in one allele coupledd with loss of the other allele (loss of heterozygosity) orr (2) deletion in both alleles (homozygous deletion). 6 Homozygouss deletion inactivates the gene in 35% of pancreaticc adenocarcinomas, and intragenic mutation coupled with losss of the second allele inactivates it in another 20%.'" 5 Comparedd with other genetic changes that occur in pancreas cancer,, inactivation of the DPC4 gene is relatively specific forfor the disease. 1 
""
Unfortunately,, searching primary tumor tissue geneticallyy for deletions can be difficult, especially in a neoplasm likee pancreatic adenocarcinoma. This is because pancreatic adenocarcinomass evoke intense desmoplastic responses, and, ass a result, most of the DNA obtained from tumor samples is actuallyy nonneoplastic DNA. Immunohistochemical analysis cann overcome this problem because it is performed in situ, andd the histologic features of the tissue are preserved. In addition,, it can be applied to formalin-fixed tissues processed inn a routine manner. Indeed, Wilentz et al 12 have recently shownn that immunohistochemical analysis for the Dpc4 proteinn performed on pancreatic resection specimens is an extremelyy sensitive and specific technique to classify DPC4 genee status.
Althoughh immunohistochemical analysis is an accurate wayy to identify inactivation of the DPC4 gene, this technique hass not been validated as a diagnostic tool. One excellent way too test this technique's usefulness is to study it in a set of biopsyy specimens from the pancreas and extrahepatic bile ductss from patients with detailed clinical follow-up. This studyy would help determine whether this technique could be usedd diagnostically in small tissue samples and could establishh a malignant diagnosis in specimens suggestive but not diagnosticc of carcinoma by examination of histologic featuress alone. Patient follow-up would be used as the "gold standard"" to verify all patients' diagnoses.
Iff Dpc4 immunohistochemical analysis could help establishh malignant diagnoses in even a fraction of the biopsyy specimens not quite diagnostic of carcinoma by histologicc features alone, patients would benefit greatly. This is so becausee in these cases, additional diagnostic procedures, suchh as repeated imaging, further biopsies, endoscopic ultrasound,, and even laparotomy, often are necessary to diagnose aa carcinoma. The morbidity and mortality attending additionall diagnostic procedures could be avoided if the use of immunohistochemicall analysis could establish a diagnosis.
Materialss and Methods

Specimenn Selection
Wee included 72 biopsy specimens from the pancreas andd extrahepatic bile ducts, obtained from 63 patients, in the study.. These specimens represented cases of pancreatic and biliaryy tract biopsies performed between September 1996 andd February 1999 at the Johns Hopkins Hospital, Baltimore,, MD. Although 125 biopsy specimens originally were availablee for study, the paraffin blocks from 53 biopsy specimenss produced slides that failed to react with the antibody (n == 11) or that did not contain enough tissue to attempt immunohistochemicall analysis (n = 42).
Thee 72 specimens were obtained from patients undergoingg endoscopic retrograde cholangiopancreatography, openn laparotomy, or radiologically guided percutaneous biopsy.. Thirty-six were from the pancreas, and 36 were fromm the extrahepatic biliary tree. Of the latter group, 18 weree from the distal common bile duct, 9 were from the proximall common bile duct, and 9 were from the common, right,, or left hepatic ducts. Thirteen patients had resections off their pancreatic or biliary masses after biopsy (10 Whipplee resections, 3 distal pancreatectomies). Tissue blockss of tumor from 6 of these resection specimens were availablee for study.
Dataa Procurement
Clinicall and pathologic data for the 72 cases were obtainedd from patients' medical records, the Johns Hopkins Oncologyy Center information system database, and the Johnss Hopkins Hospital Surgical Pathology files. Clinical andd pathologic characteristics studied included sex, race, andd age.
Immunohistochemicall Analysis
Unstainedd 4-um sections were cut from the paraffin blockk of each case and deparaffinized by routine techniques. Thee slides were treated with sodium citrate buffer (diluted to lxx from lOx heat-induced epitope retrieval buffer, Ventana BioTekk Solutions, Tucson, AZ) and then steamed for 20 minutess at 80°C. After cooling for 5 minutes, the slides weree labeled with monoclonal antibody to Dpc4 (clone B8, Santaa Cruz Biotechnology, Santa Cruz, CA) using the BioTek-Matee 1000 automated stainer (Ventana BioTek Solutions).. Each slide was labeled with a 1:100 dilution of thee antibody. The anti-Dpc4 antibody was detected by addingg biotinylated secondary antibodies, avidin-biotin complex,, and 3,3'-diaminobenzidine. Sections were counterstainedd with hematoxylin.
Twoo of us (M.T., R.E.W.) simultaneously evaluated the immunohistochemicall labeling of the biopsy specimens. We weree unaware of the previously made diagnosis on the originallyy cut H&E-stained slides for each biopsy specimen. The labelingg in each case was scored as positive or negative. Positivee labeling was defined as strong and uniform expressionn of Dpc4 in the cytoplasm of cells, with at least focal expressionn of Dpc4 in nuclei. Cases were regarded as negativee only when no expression of Dpc4 was seen in the cytoplasmicc or nuclear compartments of cells. In the 6 resection specimenss studied, the staining category of "focally positive" alsoo was used when a tumor contained 2 distinct populations off cells, those that labeled with the antibody to Dpc4 and thosee that did not. The interpretation of immunohistochemicall labeling was highly reproducible, with agreement betweenn both observers in all cases.
Normall ductal epithelium, islets of Langerhans, pancreaticc acini, lymphocytes, and stromal fibroblasts, which uniformlyy show moderate to strong expression of the Dpc4 genee product, served as positive internal controls in each of thee sections.
Statisticall Analysis
Crosss tabulations were analyzed with chi-square tests. Meanss were compared with the Wilcoxon signed rank test. Eachh test was 2-tailed.
Results s
Histologicc Diagnoses on the Biopsy Specimens
Wee included 72 biopsy specimens from the pancreas andd extrahepatic biliary tree in the study. Thirty-six specimenss originated in the pancreata of 33 patients Hmage II. islett cell tumor). Fourteen were interpreted as nonneoplastic.
Finally,, 5 of the specimens were suggestive but not diagnosticc of carcinoma. These 5 atypical biopsy specimens were fromm 5 different patients. Thirty-sixx biopsy specimens from 30 patients originatedd in the extrahepatic biliary tree. Of these, 18 were from thee distal common bile duct, 9 were from the proximal commonn bile duct, and 9 were from the common, right, or leftt hepatic ducts. Of the 18 distal common bile duct specimens,, 4 were diagnostic of adenocarcinoma, 10 were nonneoplastic,, and 4 were atypical Hmage 21, Hmage 31. Fourr of the proximal common bile duct biopsy specimens weree nonneoplastic, and 5 were atypical. There were 7 nonneoplasticc hepatic duct specimens; 1 of the hepatic duct specimenss was diagnosed as adenocarcinoma, and 1 was suggestivee of adenocarcinoma. Therefore, among the extrahepaticc biliary tract biopsy specimens, 5 contained adenocarcinoma,, 21 showed no evidence of malignancy, and 10 weree atypical. The 10 atypical biopsy specimens were from 77 different patients. 
Patientt Diagnoses After Follow-up
Eachh of the 63 patients was followed up clinically after hiss or her original biopsy diagnosis. For the 22 patients who hadd at least 1 biopsy specimen diagnostic of a neoplasm, diagnosess were confirmed by clinical and radiologic followupp (n = 19) or histologic examination of a resection specimenn (n = 3). Of the 30 patients without evidence of malignancyy on any of their 33 biopsy specimens, 11 subsequently weree proved to have a malignant neoplasm, most likely missedd by sampling error in the biopsy. These malignant neoplasmss were verified by clinical follow-up (n = 7) or by histologicc examination of a subsequent resection specimen (nn = 4). One of these malignant neoplasms actually was renal celll carcinoma metastatic to the pancreas, confirmed on examinationn of a Whipple specimen.
Thee 12 patients with biopsies interpreted as "atypical" alsoo were carefully followed up. Two of these patients had noo evidence of cancer, even after close clinical follow-up for 455 months (n = 1) or a Whipple resection (n = 1). However, 100 of the patients did have cancer, diagnosed by clinical follow-upp (n = 6), histologic examination of a Whipple resectionn specimen (n = 3), or a synchronous diagnostic biopsyy (n = 1). Nine of the 10 cancers were primary carcinomas;; 1 patient with a biopsy interpreted as atypical actuallyy had a colon cancer metastatic to the distal common bile duct.. One of the 9 primary carcinomas was an invasive adenocarcinomaa that arose in association with an intraductal papillaryy mucinous neoplasm. Finally, I patient had 4 separatee biopsy specimens suggestive but not diagnostic of cancer;; this patient was 1 of the 6 found to have adenocarcinomaa on clinical follow-up.
Inn summary, 42 patients had evidence of a neoplasm. In alll cases but 3 (islet cell tumor, metastatic colon cancer, metastaticc renal cell carcinoma), the neoplasm was a primary pancreaticc or biliary adenocarcinoma or variant (adenosquamouss carcinoma). However, for 11 patients with a malignant neoplasm,, the cancer was missed by biopsy, and another 9 biopsyy specimens were interpreted as atypical, never accompaniedd by a biopsy diagnostic of cancer. Twenty-one patients hadd no definitive evidence of malignant neoplasm revealed byy biopsy, clinical follow-up, or examination of a subsequent resectionn specimen.
Immunohistochemicall Analysis
Twelvee (17%) of 72 biopsy specimens included in the studyy showed loss of Dpc4 expression. Eleven (52%) of 21 biopsyy specimens diagnostic of adenocarcinoma showed loss off Dpc4 expression. In addition, 1 (7%) of the 15 biopsy specimenss suggestive but not diagnostic of adenocarcinoma wass negative for Dpc4. None of the 35 nonneoplastic biopsy specimenss showed loss of Dpc4 expression. ITable II summarizess these immunohistochemical data.
Alll 21 patients with biopsy specimens diagnostic of adenocarcinomaa were verified to have adenocarcinoma on follow-up.. Therefore, using histologic features as the gold standard,, the sensitivity of Dpc4 immunohistochemical analysiss in identifying adenocarcinoma on biopsy was 52%. Sincee none of the benign biopsy specimens in the study showedd loss of Dpc4 expression, the specificity of the techniquee was 100%.
Thee atypical biopsy specimen showing loss of Dpc4 expressionn originally was diagnosed as atypical because significantt crush artifact precluded a definitive diagnosis of cancerr (Image 2). The biopsy came from a 52-year-old Hispanicc man who later was clinically shown to have adenocarcinomaa of the distal common bile duct. This patient died 5 monthss after his biopsy. It is important to note that this patient didd not have any simultaneous biopsy samples that were diagnosticc of a malignancy. Therefore, immunohistochemical analysiss helped establish a subsequently proven diagnosis of adenocarcinomaa in 1 patient whose biopsy was not diagnostic off adenocarcinoma by histologic features alone.
cc II Correlationn Between Pathological Diagnosis and Dpc4 Status off Biopsy Specimens From the Pancreas and Extrahepalic Bilee Ducts
Immunohistochemicall Analysis of Resection Specimens
Tissuee blocks from 1 distal pancreatectomy and 5 Whipplee specimens performed after biopsies were taken weree available for immunolabeling and comparison with the biopsyy material. The Dpc4 status in slides from each resectionn specimen matched that in the corresponding original biopsyy specimen. For example, the islet cell tumor seen both withinn the distal pancreatectomy and the corresponding originall biopsy specimen expressed the Dpc4 protein. 13 Two adenocarcinomass of the distal common bile duct witli intact Dpc44 expression were identified within Whipple resections thatt were performed after benign diagnoses were made on biopsy;; these benign biopsy specimens of course showed intactt Dpc4 expression.
Threee Whipple resections completed after the identificationn of atypical cells in biopsy specimens also were concordantt with their corresponding Dpc4-positive biopsy specimens.. In 2 of these Whipple resection specimens, both areas off in situ and infiltrating adenocarcinoma were diffusely positivee with the Dpc4 stain. In the other resection specimen, thee invasive adenocarcinoma of the pancreas was only locallyy positive, with some areas showing intact expression andd other areas showing loss of Dpc4 expression.
Clinicall Characteristics
Thee clinical characteristics of patients with malignant biopsyy specimens that showed intact Dpc4 expression, malignantt biopsy specimens that showed loss of Dpc4 expression,, atypical biopsy specimens, and benign biopsy specimenss were compared. These characteristics are summarizedd in ITable 21. There were no significant differences amongg these 4 groups with respect to age (P = 1.000, Wilcoxonn signed rank test), sex (P = .205, chi-square test), or racee (P = .338, chi-square test).
Discussion n
Approximatelyy half of the adenocarcinomas of the pancreass and extrahepatic biliary tree have inactivated DPC4 genes. 5 Dalaa arc pu-n as number (percentage) unless otherwise indicated. The inial numbers of patients and biopsy specimens do not always match the numbers in the ten, bee; somee patients had multiple specimens that did not always have the same diagnosis. In the tent, patients are classified according to their most 'serious" leg. malignant or atypical)) diagnosis ** This category includes I patient with adenosquamous carcinoma and I with islet cell tumor: both showed intact Dpc4 expression. allelesalleles (homozygous deletion) or by mutation in one allele combinedd with loss of the other allele (loss of heterozygosity). 66 lnactivation of the DPC4 gene is important in these cancerss because compared with alterations in other genes, suchh as K-rcw, pl6, and p53, changes in DPC4 are relatively specificc for pancreatic adenocarcinoma.' 3 -71014 Thee genetic analysis of the DNA from an infiltrating cancerr for DPC4 alterations can be greatly limited by low neoplasticc cellularity. Because it is technically less cumbersomee and more widely available than are genetic assays, immunohistochemicall analysis of the gene product is an excellentt way to avoid this problem. Indeed, in a recent study,, Wilentz et al 12 found that immunohistochemical analysiss for the Dpc4 gene product is a highly specific and sensitivee marker for DPC4 gene inactivation.
However,, even though the technique is highly sensitive andd specific, the role of Dpc4 immunohistochemical analysis inn clinical diagnosis has yet to be proven. We undertook this projectt to determine whether this technique is valuable diagnosticallyy by studying it in a frequently encountered difficult clinicall setting. By studying Dpc4 immunohistochemical analysiss in benign, malignant, and atypical biopsy specimens off the pancreas and extrahepatic biliary tree, we hoped to showw that Dpc4 immunohistochemical analysis can be a valuablee adjunct to routine histologic examination in establishingg the diagnosis of cancer in small tissue samples, especiallyy those suggestive but not diagnostic of carcinoma by histologicc examination alone.
Indeed,, we showed in this study that immunohistochemicall labeling for Dpc4 is a valuable technique in the diagnosiss of adenocarcinoma in biopsy specimens from the pancreass and extrahepatic biliary tree. Importantly, the techniquee is 100% specific. In contrast, immunohistochemical analysiss is only 52% sensitive. This low sensitivity is not surprising,, given that only half of all pancreatic and biliary adenocarcinomass actually show inactivation of the DPC4 gene.. More important, however, is that immunohistochemicall analysis for Dpc4 successfully established the diagnosis off adenocarcinoma in a patient whose distal common bile ductt biopsy specimen was suggestive but not diagnostic of adenocarcinomaa by histologic examination alone. The presencee of adenocarcinoma in this patient was verified by clinicall follow-up.
Therefore,, this study leads to two important conclusions aboutt Dpc4 immunohistochemical analysis in biopsy specimenss from the pancreas and biliary tract. First, the technique iss a specific marker for adenocarcinoma of the pancreas and biliaryy tract. Thus, loss of Dpc4 expression in a biopsy of the pancreass or biliary tract helps establish the diagnosis of cancer.. Furthermore, because Dpc4 inactivation is relatively specificc for periampullary cancer, loss of Dpc4 expression signalss the probability that the cancer is primary to the
